N/A
Completed N=112
ARB, ACEi, DRi Effects on COVID-19 Course Disease
Source: ClinicalTrials.gov NCT04364984 ↗Enrolled (actual)
112
Serious AEs
23.2%
Results posted
Feb 2022
Primary outcomePrimary: Level of BP in mm Hg — 136; 138; 34; 82 mm Hg
Summary
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2. receiving ARBs 3. receiving DIR.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Level of BP in mm Hg |
136; 138; 34; 82; 83; 82 | — |
| SECONDARY Number of Patients With Fever Above 37.2 on COVID-19 Course |
32; 39; 30 | — |
| SECONDARY Number of Patients With Cough in COVID-19 Course |
29; 30; 28 | — |
| SECONDARY Number of Patients With Throat Pain in COVID-19 Course |
19; 21; 16 | — |
| SECONDARY Number of Patients With Diarrhea Inf COVID-19 Course |
3; 4; 1 | — |
| SECONDARY Number of Patients Who Need to Apply to Hospital in COVID-19 Course |
2; 2; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Hypertensive person, stage 1-2
Exclusion Criteria
- Hypertensive subjects, stage 3, HF (NYHA) 3-4
Data sourced from ClinicalTrials.gov (NCT04364984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.